Origin/Publisher:
EUROPEAN COMMISSION, ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL, Consumer goods, Pharmaceuticals
Document Type:Annex EU Guideline to GMP
Content:control of starting materials, storage and processing of herbal medicinal products
ANTI AGING therapies
CRISPR/Cas9 in Treating Monogenic Disorders: A Breakthrough in Sickle Cell Anemia Therapy
CRISPR/Cas9, a revolutionary gene-editing technology, offers new hope for treating monogenic disorders like sickle cell anemia. By precisely targeting and correcting the mutated gene responsible for the disease, CRISPR/Cas9 has the potential to provide a permanent cure, offering significant implications for patients and healthcare systems.
